Cargando…

Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53

BACKGROUND: Improved mesothelioma patient survival will require development of novel and more effective pharmacological interventions. TP53 genomic mutations are uncommon in mesothelioma, and recent data indicate that p53 remains functional, and therefore is a potential therapeutic target in these c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ou, Wen-Bin, Lu, Minmin, Eilers, Grant, Li, Hailong, Ding, Jiongyan, Meng, Xuli, Wu, Yuehong, He, Quan, Sheng, Qing, Zhou, Hai-Meng, Fletcher, Jonathan A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104897/ https://www.ncbi.nlm.nih.gov/pubmed/27736841 http://dx.doi.org/10.1038/bjc.2016.331

Ejemplares similares

MDM2 is an important prognostic and predictive factor for platin–pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53
por: Walter, R F H, et al.
Publicado: (2015)

HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status
por: Ou, Wen-Bin, et al.
Publicado: (2015)

p53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumours
por: Dimitriadi, M, et al.
Publicado: (2008)

AXL Inactivation Inhibits Mesothelioma Growth and Migration via Regulation of p53 Expression
por: Song, Wei, et al.
Publicado: (2020)

Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion
por: Meng, X N, et al.
Publicado: (2009)

Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3
por: Yang, Peipei, et al.
Publicado: (2016)

Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
por: Cui, Ai, et al.
Publicado: (2014)

Overexpression and altered glycosylation of MUC1 in malignant mesothelioma
por: Creaney, J, et al.
Publicado: (2008)

SV40 associated miRNAs are not detectable in mesotheliomas
por: Gee, G V, et al.
Publicado: (2010)

Evaluating the effect of immune cells on the outcome of patients with mesothelioma
por: Chee, Serena J, et al.
Publicado: (2017)

MDM2 promotes epithelial–mesenchymal transition and metastasis of ovarian cancer SKOV3 cells
por: Chen, Ying, et al.
Publicado: (2017)

Markers for the non-invasive diagnosis of mesothelioma: a systematic review
por: van der Bij, S, et al.
Publicado: (2011)

Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma
por: Meniawy, T M, et al.
Publicado: (2013)

STAAR: improving the reliability of care coordination and reducing hospital readmissions in an academic medical centre
por: Carter, Jocelyn Alexandria, et al.
Publicado: (2015)

Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion
por: Tsuji, S, et al.
Publicado: (2010)

The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma
por: Dalton, L E, et al.
Publicado: (2013)

Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma
por: Ghanim, B, et al.
Publicado: (2014)

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis
por: Kirschner, Michaela B, et al.
Publicado: (2015)

Overexpression of connexin 43 reduces melanoma proliferative and metastatic capacity
por: Tittarelli, A, et al.
Publicado: (2015)

Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells
por: Hoda, M A, et al.
Publicado: (2012)

CD74: a new prognostic factor for patients with malignant pleural mesothelioma
por: Otterstrom, C, et al.
Publicado: (2014)

Genomic instability and proliferative activity as risk factors for distant metastases in breast cancer
por: Li, L, et al.
Publicado: (2008)

Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism
por: Beesley, A H, et al.
Publicado: (2009)

Genetic ablation of β-catenin inhibits the proliferative phenotype of mouse liver adenomas
por: Singh, Y, et al.
Publicado: (2014)

Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53
por: Walter, Robert F. H., et al.
Publicado: (2018)

High levels of MDM2 are not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines.
por: Ungar, S., et al.
Publicado: (1996)

The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma
por: Pinato, D J, et al.
Publicado: (2013)

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
por: Zhou, S, et al.
Publicado: (2014)

Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells
por: Johansson, D, et al.
Publicado: (2010)

Technology-enabled examinations of cardiac rhythm, optic nerve, oral health, tympanic membrane, gait and coordination evaluated jointly with routine health screenings: an observational study at the 2015 Kumbh Mela in India
por: Shah, Pratik, et al.
Publicado: (2018)

Diagnostic utility of appetite loss in addition to existing prediction models for community-acquired pneumonia in the elderly: a prospective diagnostic study in acute care hospitals in Japan
por: Takada, Toshihiko, et al.
Publicado: (2017)

A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma
por: Kao, Steven C, et al.
Publicado: (2016)

Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer
por: Hofstetter, G, et al.
Publicado: (2011)

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
por: Hirose, Mitsuaki, et al.
Publicado: (2014)

Low expression of the putative tumour suppressor spinophilin is associated with higher proliferative activity and poor prognosis in patients with hepatocellular carcinoma
por: Aigelsreiter, A, et al.
Publicado: (2013)

Biliverdin's regulation of reactive oxygen species signalling leads to potent inhibition of proliferative and angiogenic pathways in head and neck cancer
por: Zheng, J, et al.
Publicado: (2014)

Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction
por: Thayer, Kelly M., et al.
Publicado: (2016)

Regulation of p53: a collaboration between Mdm2 and MdmX
por: Pei, Dongsheng, et al.
Publicado: (2012)

Regulation of kidney development by the Mdm2/Mdm4–p53 axis
por: El-Dahr, Samir, et al.
Publicado: (2017)

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
por: Mrkvová, Zuzana, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lc8ggcapii6qdm3qrsm5bkl4ih